EGFR and head and neck squamous cell carcinoma: Even poziotinib (HM781–36B), an irreversible EGFR inhibitor, has been studied in different clinical trials, showing efficacy in NSCLC [13] and in recurrent and/or metastatic head and neck SCC (R/M-HNSCC) [14].